ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
May 9, 2019 8:30 AM EDTBAUDETTE, Minn., May 9, 2019 /PRNewswire/ --
For the first quarter 2019:
Net revenues of $52.9 million, an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share of $0.04 Record adjusted non-GAAP EBITDA of $22.3 million Adjusted non-GAAP diluted earnings per share of $1.30ANI Pharmaceuticals, Inc. ("ANI")Â (NASDAQ: ANIP) today reported its financial results for the three months ended March 31, 2019 and reaffirmed its 2019 financial guidance. The Company will host its earnings conference call this morning, May 9,... More
